Top

Journal of Endocrinological Investigation

Published in:

01-09-2016 | Review

Testosterone supplementation and body composition: results from a meta-analysis of observational studies

Authors: G. Corona, V. A. Giagulli, E. Maseroli, L. Vignozzi, A. Aversa, M. Zitzmann, F. Saad, E. Mannucci, M. Maggi

Published in: Journal of Endocrinological Investigation | Issue 9/2016

Abstract

Purpose

The concept of testosterone (T) supplementation (TS) as a new anti-obesity medication in men with testosterone deficiency syndrome (TDS) is emerging. Data from placebo-controlled trials are more conflicting. The aim of this study is to systematically review and meta-analyze available observational and register studies reporting data on body composition in studies on TS in TDS.

Methods

An extensive MEDLINE, Embase, and Cochrane search was performed including the following words: “testosterone” and “body composition.” All observational studies comparing the effect of TS on body weight and other body composition and metabolic endpoints were considered.

Results

Out of 824 retrieved articles, 32 were included in the study enrolling 4513 patients (mean age 51.7 ± 6.1 years). TS was associated with a time-dependent reduction in body weight and waist circumference (WC). The estimated weight loss and WC reduction at 24 months were −3.50 [−5.21; −1.80] kg and −6.23 [−7.94; −4.76] cm, respectively. TS was also associated with a significant reduction in fat and with an increase in lean mass as well as with a reduction in fasting glycemia and insulin resistance. In addition, an improvement of lipid profile (reduction in total cholesterol as well as of triglyceride levels and an improvement in HDL cholesterol levels) and in both systolic and diastolic blood pressure was observed.

Conclusions

Present data support the view of a positive effect of TS on body composition and on glucose and lipid metabolism. In addition, a significant effect on body weight loss was observed, which should be confirmed by a specifically designed RCT.

Available only for authorised users

Dietz WH, Baur LA, Hall K, Puhl RM, Taveras EM, Uauy R et al (2015) Management of obesity: improvement of health-care training and systems for prevention and care. Lancet 385:2521–2533CrossRefPubMed

Corona G, Rastrelli G, Filippi S, Vignozzi L, Mannucci E, Maggi M (2014) Erectile dysfunction and central obesity: an Italian perspective. Asian J Androl 16:581–591CrossRefPubMedPubMedCentral

Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, Commerford P, INTERHEART Study Investigators et al (2005) Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case–control study. Lancet 366:1640–1649CrossRefPubMed

Corona G, Rastrelli G, Morelli A, Vignozzi L, Mannucci E, Maggi M (2011) Hypogonadism and metabolic syndrome. J Endocrinol Investig 34:557–567CrossRef

Corona G, Vignozzi L, Sforza A, Mannucci E, Maggi M (2015) Obesity and late-onset hypogonadism. Mol Cell Endocrinol 418:120–133CrossRefPubMed

Brand JS, Rovers MM, Yeap BB, Schneider HJ, Tuomainen TP, Haring R et al (2014) Testosterone, sex hormone-binding globulin and the metabolic syndrome in men: an individual participant data meta-analysis of observational studies. PLoS ONE 9:e100409CrossRefPubMedPubMedCentral

Rastrelli G, Corona G, Mannucci E, Maggi M (2015) Vascular and chronological age in subjects with erectile dysfunction: a cross-sectional study. J Sex Med 12:2303–2312CrossRefPubMed

Iglesias P, Prado F, Macías MC, Guerrero MT, Muñoz A, Ridruejo E et al (2014) Hypogonadism in aged hospitalized male patients: prevalence and clinical outcome. J Endocrinol Invest 37:135–141CrossRefPubMed

Calderón B, Gómez-Martín JM, Vega-Piñero B, Martín-Hidalgo A, Galindo J, Luque-Ramírez M et al (2016) Prevalence of male secondary hypogonadism in moderate to severe obesity and its relationship with insulin resistance and excess body weight. Andrology 4:62–67CrossRefPubMed

10.

Rastrelli G, Corona G, Mannucci E, Maggi M (2016) Vascular and chronological age in men with erectile dysfunction: a longitudinal study. J Sex Med 13(2):200–208CrossRefPubMed

11.

Corona G, Rastrelli G, Vignozzi L, Mannucci E, Maggi M (2012) How to recognize late-onset hypogonadism in men with sexual dysfunction. Asian J Androl 14:251–259CrossRefPubMedPubMedCentral

12.

Saad F, Aversa A, Isidori AM, Gooren LJ (2012) Testosterone as potential effective therapy in treatment of obesity in men with testosterone deficiency: a review. Curr Diabetes Rev 8:131–143CrossRefPubMedPubMedCentral

13.

Zarotsky V, Huang MY, Carman W, Morgentaler A, Singhal PK, Coffin D et al (2014) Systematic literature review of the risk factors, comorbidities, and consequences of hypogonadism in men. Andrology 2:819–834CrossRefPubMed

14.

Isidori AM, Balercia G, Calogero AE, Corona G, Ferlin A, Francavilla S et al (2015) Outcomes of androgen replacement therapy in adult male hypogonadism: recommendations from the Italian society of endocrinology. J Endocrinol Investig 38:103–112CrossRef

15.

Maneschi E, Morelli A, Filippi S, Cellai I, Comeglio P, Mazzanti B et al (2012) Testosterone treatment improves metabolic syndrome-induced adipose tissue derangements. J Endocrinol 215:347–362CrossRefPubMed

16.

Saad F, Gooren L, Haider A, Yassin A (2007) An exploratory study of the effects of 12 month administration of the novel long-acting testosterone undecanoate on measures of sexual function and the metabolic syndrome. Arch Androl 53:353–357CrossRefPubMed

17.

Saad F, Gooren LJ, Haider A, Yassin A (2008) A dose-response study of testosterone on sexual dysfunction and features of the metabolic syndrome using testosterone gel and parenteral testosterone undecanoate. J Androl 29:102–105CrossRefPubMed

18.

Saad F, Haider A, Doros G, Traish A (2013) Long-term treatment of hypogonadal men with testosterone produces substantial and sustained weight loss. Obesity 21:1975–1981 (Silver Spring) CrossRefPubMed

19.

Francomano D, Lenzi A, Aversa A (2014) Effects of five-year treatment with testosterone undecanoate on metabolic and hormonal parameters in ageing men with metabolic syndrome. Int J Endocrinol 2014:527470CrossRefPubMedPubMedCentral

20.

Yassin DJ, Doros G, Hammerer PG, Yassin AA (2014) Long-term testosterone treatment in elderly men with hypogonadism and erectile dysfunction reduces obesity parameters and improves metabolic syndrome and health-related quality of life. J Sex Med 11:1567–1576CrossRefPubMed

21.

Zitzmann M, Saad F, Kliesch S (2014) Long-term treatment with testosterone undecanoate injections leads to sustained weight loss and improvement of metabolic syndrome parameters in 381 hypogonadal men. J Sex Med 11(Suppl. 1):7

22.

Haider A, Saad F, Doros G, Gooren L (2014) Hypogonadal obese men with and without diabetes mellitus type 2 lose weight and show improvement in cardiovascular risk factors when treated with testosterone: an observational study. Obes Res Clin Pract 8:e339–e349CrossRefPubMed

23.

Traish AM, Haider A, Doros G, Saad F (2014) Long-term testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome: an observational, long-term registry study. Int J Clin Pract 68:314–329CrossRefPubMed

24.

Saad F, Yassin A, Doros G, Haider A (2016) Effects of long-term treatment with testosterone on weight and waist size in 411 hypogonadal men with obesity classes I-III: observational data from two registry studies. Int J Obes 40:162–170CrossRef

25.

Corona G, Maseroli E, Maggi M (2014) Injectable testosterone undecanoate for the treatment of hypogonadism. Expert Opin Pharmacother 15:1903–1926CrossRefPubMed

26.

Neff KJ, le Roux CW (2013) Bariatric surgery: a best practice article. J Clin P athol 66:90–98CrossRef

27.

Corona G, Giagulli VA, Maseroli E, Vignozzi L, Aversa A, Zitzmann M, Saad F, Mannucci E, Maggi M (2016) THERAPY OF ENDOCRINE DISEASE: testosterone supplementation and body composition: results from a meta-analysis study. Eur J Endocrinol 174(3):R99–R116CrossRefPubMed

28.

Cohen AT, Goto S, Schreiber K, Torp-Pedersen C (2015) Why do we need observational studies of everyday patients in the real-life setting? Eur Heart J Suppl 17(Supplement D):D2–D8CrossRef

29.

Cox JL, Pieper K (2015) Harnessing the power of real-life data. Eur Heart J Supp. 17(Supplement D):D9–D14CrossRef

30.

Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group et al (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA 283:2008–2012CrossRefPubMed

31.

Valdemarsson S, Hedner P, Nilsson-Ehle P (1987) Increase in hepatic lipase activity after testosterone substitution in men with hypogonadism of pituitary origin. Acta Med Scand. 221:363–366CrossRefPubMed

32.

Rebuffé-Scrive M, Mårin P, Björntorp P (1991) Effect of testosterone on abdominal adipose tissue in men. Int J Obes 15:791–795

33.

Forbes GB, Porta CR, Herr BE, Griggs RC (1992) Sequence of changes in body composition induced by testosterone and reversal of changes after drug is stopped. JAMA 267:397–399CrossRefPubMed

34.

Mårin P, Krotkiewski M, Björntorp P (1992) Androgen treatment of middle-aged, obese men: effects on metabolism, muscle and adipose tissues. Eur J Med 1:329–336PubMed

35.

Brodsky IG, Balagopal P, Nair KS (1996) Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men—a clinical research center study. J Clin Endocrinol Metab 81:3469–3475PubMed

36.

Katznelson L, Finkelstein JS, Schoenfeld DA, Rosenthal DI, Anderson EJ, Klibanski A (1996) Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab 81:4358–4365PubMed

37.

Wang C, Eyre DR, Clark R, Kleinberg D, Newman C, Iranmanesh A et al (1996) Sublingual testosterone replacement improves muscle mass and strength, decreases bone resorption, and increases bone formation markers in hypogonadal men—a clinical research center study. J Clin Endocrinol Metab 81:3654–3662PubMed

38.

Zgliczynski S, Ossowski M, Slowinska-Srzednicka J, Brzezinska A, Zgliczynski W, Soszynski P et al (1996) Effect of testosterone replacement therapy on lipids and lipoproteins in hypogonadal and elderly men. Atherosclerosis 121:35–43CrossRefPubMed

39.

Bhasin S, Storer TW, Berman N, Yarasheski KE, Clevenger B, Phillips J et al (1997) Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. J Clin Endocrinol Metab 82:407–413PubMed

40.

Tan KC, Shiu SW, Pang RW, Kung AW (1998) Effects of testosterone replacement on HDL subfractions and apolipoprotein A-I containing lipoproteins. Clin Endocrinol (Oxf). 48:187–194CrossRefPubMed

41.

Brill KT, Weltman AL, Gentili A, Patrie JT, Fryburg DA, Hanks JB et al (2002) Single and combined effects of growth hormone and testosterone administration on measures of body composition, physical performance, mood, sexual function, bone turnover, and muscle gene expression in healthy older men. J Clin Endocrinol Metab 87:5649–5657CrossRefPubMed

42.

Minnemann T, Schubert M, Hübler D, Gouni-Berthold I, Freude S, Schumann C et al (2007) A four-year efficacy and safety study of the long-acting parenteral testosterone undecanoate. Aging Male 10:155–158CrossRefPubMed

43.

Naharci MI, Pinar M, Bolu E, Olgun A (2007) Effect of testosterone on insulin sensitivity in men with idiopathic hypogonadotropic hypogonadism. Endocr Pract 13:629–635CrossRefPubMed

44.

La Vignera S, Calogero AE, Condorelli R, Lanzafame F, Giammusso B, Vicari E (2009) Andrological characterization of the patient with diabetes mellitus. Minerva Endocrinol 34:1–9PubMed

45.

Moon DG, Park MG, Lee SW, Park K, Park JK, Kim SW, Park NC et al (2010) The efficacy and safety of testosterone undecanoate (Nebido^®) in testosterone deficiency syndrome in Korean: a multicenter prospective study. J Sex Med 7(6):2253–2260CrossRef

46.

Permpongkosol S, Tantirangsee N, Ratana-olarn K (2010) Treatment of 161 men with symptomatic late onset hypogonadism with long-acting parenteral testosterone undecanoate: effects on body composition, lipids, and psychosexual complaints. J Sex Med 7:3765–3774CrossRefPubMed

47.

Garcia JA, Sanchez PE, Fraile C, Escovar P (2011) Testosterone undecanoate improves erectile dysfunction in hypogonadal men with the metabolic syndrome refractory to treatment with phosphodiesterase type 5 inhibitors alone. Andrologia 43:293–296CrossRefPubMed

48.

Schwarz ER, Willix RD Jr (2011) Impact of a physician-supervised exercise-nutrition program with testosterone substitution in partial androgen-deficient middle-aged obese men. J Geriatr Cardiol 8:201–206PubMedPubMedCentral

49.

Arafa M, Zohdy W, Aboulsoud S, Shamloul R (2012) Prevalence of late-onset hypogonadism in men with type 2 diabetes mellitus. Andrologia. 44(Suppl 1):756–763CrossRefPubMed

50.

Schroeder ET, He J, Yarasheski KE, Binder EF, Castaneda-Sceppa C, Bhasin S et al (2012) Value of measuring muscle performance to assess changes in lean mass with testosterone and growth hormone supplementation. Eur J Appl Physiol 112:1123–1131CrossRef

51.

Jo DG, Lee HS, Joo YM, Seo JT (2013) Effect of testosterone replacement therapy on bone mineral density in patients with Klinefelter syndrome. Yonsei Med J 54:1331–1335CrossRefPubMedPubMedCentral

52.

Ko YH, Moon DG, Moon KH (2013) Testosterone replacement alone for testosterone deficiency syndrome improves moderate lower urinary tract symptoms: one year follow-up. World J Mens Health 31:47–52CrossRefPubMedPubMedCentral

53.

Rodriguez-Tolrà J, Torremadé Barreda J, del Rio L, di Gregorio S, Franco Miranda E (2013) Effects of testosterone treatment on body composition in males with testosterone deficiency syndrome. Aging Male. 16:184–190CrossRefPubMed

54.

Tirabassi G, Delli Muti N, Corona G, Maggi M, Balercia G (2013) Androgen receptor gene CAG repeat polymorphism regulates the metabolic effects of testosterone replacement therapy in male postsurgical hypogonadotropic hypogonadism. Int J Endocrinol. 2013:816740CrossRefPubMedPubMedCentral

55.

Zitzmann M, Mattern A, Hanisch J, Gooren L, Jones H, Maggi M (2013) IPASS: a study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1,438 men. J Sex Med 10:579–588CrossRefPubMed

56.

Pexman-Fieth C, Behre HM, Morales A, Kan-Dobrosky N, Miller MG (2014) A 6-month observational study of energy, sexual desire, and body proportions in hypogonadal men treated with a testosterone 1% gel. Aging Male 17:1–11CrossRefPubMed

57.

Conway AJ, Boylan LM, Howe C, Ross G, Handelsman DJ (1988) Randomized clinical trial of testosterone replacement therapy in hypogonadal men. Int J Androl 11:247–264CrossRefPubMed

58.

Sorva R, Kuusi T, Taskinen MR, Perheentupa J, Nikkilä EA (1988) Testosterone substitution increases the activity of lipoprotein lipase and hepatic lipase in hypogonadal males. Atherosclerosis 69:191–197CrossRefPubMed

59.

Ozata M, Yildirimkaya M, Bulur M, Yilmaz K, Bolu E, Corakci A et al (1996) Effects of gonadotropin and testosterone treatments on Lipoprotein(a), high density lipoprotein particles, and other lipoprotein levels in male hypogonadism. J Clin Endocrinol Metab 81:3372–3378PubMed

60.

Tripathy D, Shah P, Lakshmy R, Reddy KS (1998) Effect of testosterone replacement on whole body glucose utilisation and other cardiovascular risk factors in males with idiopathic hypogonadotrophic hypogonadism. Horm Metab Res 30:642–645CrossRefPubMed

61.

Andrade ES Jr, Clapauch R, Buksman S (2009) Short term testosterone replacement therapy improves libido and body composition. Arq Bras Endocrinol Metabol 53:996–1004CrossRefPubMed

62.

Wu XY, Mao JF, Lu SY, Zhang Q, Shi YF (2009) Testosterone replacement therapy improves insulin sensitivity and decreases high sensitivity C-reactive protein levels in hypogonadotropic hypogonadal young male patients. Chin Med J (Engl) 122:2846–2850

63.

Cochrane Handbook for Systematic Reviews of Interventions. Available at http://www.cochrane-handbook.org. Last accessed 26 Dec 2015

64.

Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088–1101CrossRefPubMed

65.

Egger M, Smith GD, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634CrossRefPubMedPubMedCentral

66.

Cohen J (1977) Statistical power analysis for the behavioral sciences. Academic Press, New York

67.

Yassin A, Doros G (2013) Testosterone therapy in hypogonadal men results in sustained and clinically meaningful weight loss. Clin Obes 3:73–83CrossRefPubMedPubMedCentral

68.

Crewther BT, Kilduff LP, Cook CJ (2014) Trained and untrained males show reliable salivary testosterone responses to a physical stimulus, but not a psychological stimulus. J Endocrinol Investig 37:1065–1072CrossRef

69.

Sgrò P, Romanelli F, Felici F, Sansone M, Bianchini S, Buzzachera CF, Baldari C, Guidetti L, Pigozzi F, Lenzi A, Di Luigi L (2014) Testosterone responses to standardized short-term sub-maximal and maximal endurance exercises: issues on the dynamic adaptive role of the hypothalamic-pituitary-testicular axis. J Endocrinol Investig 37:13–24CrossRef

70.

Snyder PJ, Bhasin S, Cunningham GR, Matsumoto AM, Stephens-Shields AJ, Cauley JA et al (2016) Effects of testosterone treatment in older men. N Engl J Med 374:611–624CrossRefPubMed

71.

Corona G, Rastrelli G, Maggi M (2015) The pharmacotherapy of male hypogonadism besides androgens. Expert Opin Pharmacother 16:369–487. Erratum in: Expert Opin Pharmacother. 2015;16:941. Ratrelli, Giulia [corrected to Rastrelli, Giulia]

72.

Corona G, Rastrelli G, Vignozzi L, Maggi M (2012) Emerging medication for the treatment of male hypogonadism. Expert Opin Emerg Drugs 17:239–259CrossRefPubMed

73.

Rastrelli G, Giovannini L, Calogero AE, Gianfrilli D, Serra E, Pizzocaro A, Giagulli VA, Motta G, Vancieri G, Sperandio A, Andò S, Selice R, Luca G, Cocchiara F, Canale D, Maggi M (2016) Predictors and clinical consequences of starting androgen therapy in men with low testosterone: results from the SIAMO-NOI registry. J Endocrinol Invest 39(6):695–708CrossRefPubMed

74.

Corona G, Maseroli E, Rastrelli G, Isidori AM, Sforza A, Mannucci E et al (2014) Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis. Expert Opin Drug Saf 13:1327–1351CrossRefPubMed

75.

Calof OM, Singh AB, Lee ML, Kenny AM, Urban RJ, Tenover JL et al (2005) Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci 60:1451–1457CrossRefPubMed

76.

Haddad RM, Kennedy CC, Caples SM, Tracz MJ, Boloña ER, Sideras K et al (2007) Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc 82:29–39CrossRefPubMed

77.

Fernández-Balsells MM, Murad MH, Lane M, Lampropulos JF, Albuquerque F, Mullan RJ et al (2010) Clinical review 1: adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab 95:2560–2575CrossRefPubMed

78.

Borst SE, Shuster JJ, Zou B, Ye F, Jia H, Wokhlu A, Yarrow JF (2014) Cardiovascular risks and elevation of serum DHT vary by route of testosterone administration: a systematic review and meta-analysis. BMC Med 12:211CrossRefPubMedPubMedCentral

79.

Xu L, Freeman G, Cowling BJ, Schooling CM (2013) Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Med 11:108CrossRefPubMedPubMedCentral

Title: Testosterone supplementation and body composition: results from a meta-analysis of observational studies
Authors: G. Corona
V. A. Giagulli
E. Maseroli
L. Vignozzi
A. Aversa
M. Zitzmann
F. Saad
E. Mannucci
M. Maggi
Publication date: 01-09-2016
Publisher: Springer International Publishing
Published in: Journal of Endocrinological Investigation / Issue 9/2016
Electronic ISSN: 1720-8386
DOI: https://doi.org/10.1007/s40618-016-0480-2

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 9/2016

Role of “old” pharmacological agents in the treatment of Cushing’s syndrome

Spironolactone and intermenstrual bleeding in polycystic ovary syndrome with normal BMI

Radiofrequency ablation for benign thyroid nodules

SIAD: practical recommendations for diagnosis and management

Erratum to: Evidence for decreased expression of APPL1 associated with reduced insulin and adiponectin receptors expression in PCOS patients

Evidence for decreased expression of APPL1 associated with reduced insulin and adiponectin receptors expression in PCOS patients

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials